NCT01388543View on ClinicalTrials.gov

Genetics and HIV-1 Protease Inhibitors

PHASE4CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions
HIV
Interventions
DRUG

Atazanavir

Atazanavir 400mg once daily for 7 days followed by atazanavir 300mg plus ritonavir 100mg for 7 days

Trial Locations (1)

80045

University of Colorado Denver and Health Sciences Center, Aurora

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

University of Colorado, Denver

OTHER

NCT01388543 - Genetics and HIV-1 Protease Inhibitors | Biotech Hunter | Biotech Hunter